The efficacy and functions of Sonidegib

Sonidegib is a cancer drug used to treat adults with basal cell carcinoma (a type of skin cancer) that is locally advanced (has begun to spread nearby) and cannot be treated with surgery or radiation therapy (radiation therapy). SonidegibContains the active substancesonidegib. Solidegib was studied in a major study involving 230 patients with locally advanced or metastatic (spread to other parts of the body) basal cell carcinoma.

The patient was started on two different doses of solidegib: 200 or 800 mg once daily. The main measure of effectiveness is response to treatment, based on reduction in tumor size and improvement in other signs of cancer; treatment is considered sufficiently effective if the response rate is at least 30%. Among those with locally advanced basal cell carcinoma, approximately 56% (37 of 66 patients) responded to treatment at the 200 mg dose and 45% (58 of 128 patients) at the 800 mg dose. Patients with metastatic cancer who started taking 200 or 800 mg of solidegib experienced response rates of less than 20%.

Solidagen is a new type of drug for treating diseases. Although the original drug Solidagen has been marketed in China, it has not yet entered the scope of medical insurance, and its price has not yet been determined. The Original drug Solidaget listed overseas, European version specificationsThe price per box of 200mg*30 tablets is around RMB 46,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. The ingredients of the two drugs are basically the same. There is currently no generic version of Solidaget produced and marketed. For specific prices and drug information, please consult Yaodei Medical Consultants.